Summary
The high prevalence of post-acute sequelae of SARS-CoV-2 infection (PASC) is a significant health concern. In particular, virus-specific immunity in patients who suffer from chronic neurologic symptoms after acute SARS-CoV-2 infection remain poorly understood. Here, we report that Neuro-PASC patients have a specific immunological signature composed of humoral and cellular responses that are biased towards different SARS-CoV-2 structural proteins compared to healthy COVID convalescents, including a significant elevation in Nucleocapsid-specific antibody and T cell responses. Interestingly, the severity of cognitive deficits or quality of life markers in Neuro-PASC patients are associated with reduced effector molecule expression in memory T cells. Furthermore, we demonstrate a sustained elevation in T cell responses to SARS-CoV-2 mRNA vaccines in Neuro-PASC patients compared with healthy COVID convalescents. These data provide a framework for the rational design of predictive biomarkers and therapeutics for long COVID syndrome.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
L.V. was supported by a T32 grant T32AR007611 from the Department of Rheumatology, Northwestern University Feinberg School of Medicine. P.P.M. is supported by a grant from the Emerging and Re-Emerging Pathogens Program (EREPP) at Northwestern University, and a grant from the National Institute on Drug Abuse (NIDA, DP2DA051912)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Northwestern University Institutional Review Board (Koralnik Lab, IRB STU00212583).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵¶ Lead contact: Lavanya Visvabharathy, Ph.D
Significant data updates to Figures 2-6; added figure S2. Added to results and discussion.
Data Availability
The data that support the findings of this study are available from the corresponding author, [LV], upon reasonable request.
